报道内地促药价透明化监管机制酝酿升级
据《经济参考报》报道,内地将进一步规范药品价格管理,完善药品价格形成机制,探索建立常态化监管机制。同时,加速推进按通用名制定医保药品支付标准并动态调整。报道引述权威人士透露,日前内地相关部门对现阶段药品价格管理工作,包括药品集中采购、价格管理、医保支付标准等方面徵求意见,意在摸清成本,促进药品合理定价。
据悉,医疗保障部门管理价格的药品类别包括化学药品、中成药、生化药品、中药饮片、医院自制剂等,其中,除麻醉药品和第一类精神药品外,其他药品的价格均实行市场调节。
按照要求,这些以市场定价的药品,经营者自主制定价格时,应自觉将价格与成本、供求相匹配,自觉保持不同品规、不同区域之间价格平衡,自觉维护价格一定时期内相对稳定。同时,监管部门此次重心在药品价格透明。未来对於药价的管理,将通过信息的互联互通进行比对,进行成本调查等,打破医药行业一直以来的数据壁垒。
此次徵求意见中透露,内地将依托省级药品集中采购平台,建设全国药品公共采购市场。未来将通过对药品统一编码、标准和功能规范,综合运用监测预警、函询约谈、成本调查、信用评价、信息披露等手段,对药品价格进行常态化监督。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.